VBI Vaccines Starts Enrollment in Phase 1/2 Study of COVID-19 Vaccine

 - Initial data from Phase 1 of the study expected by the end of Q2 2021, subject to rate of enrollment

- Adaptive Phase 1/2 study supported by previously announced contribution from Strategic Innovation Fund of Canadian Government of up to CAD$56 million

- Initiation of Phase 1/2 study of pan-coronavirus vaccine candidate, VBI-2901, anticipated later in 2021

 

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce the initiation of enrollment of its Phase 1/2 clinical study of VBI-2902, the Company’s monovalent enveloped virus-like particle (eVLP) COVID-19 vaccine candidate.

https://www.biospace.com/article/releases/vbi-vaccines-announces-initiation-of-enrollment-in-adaptive-phase-1-2-study-of-prophylactic-covid-19-vaccine-candidate-vbi-2902/